El dossier - Géminis Papeles de Salud

11. Scholdelmayer WS. Public citizen update: competition and pricing Iisues in the pharmaceutical Market. Prime Institute.
University of Minnesota, 2000. [ Links ]
12. Soger A, Socolar D. Pharmaceutical marketing and research spending: the evidence does not support PhRMA´s claims.
Presentado en: American Public Health Association Annual Meeting, 2001, Atlatanta, Gerogia. Se puede encontrar en
http:://dcc2.bumc.bu.edu/hs/ushealthreform.htm [ Links ]
13. Prescription drugs and Mass Media adversiting. NIHCM, 2001. http://www.nichm.org/ DTCbcie/2001.pdf [ Links ]
14. Bodenheimer T.Uneasy alliance: clínica investigators and the pharmaceutical industry. N Engl J Med 2000; 342: 1539-
1544 [ Links ]
15. Esteve Soler J. La industria farmacéutica como la impulsora de la I+D en el sector sanitario. Revista de la administración
sanitaria 1998; 11(7):1-9 [ Links ]
16. Ferrán Mercadé M. La financiación de las sociedades científicas y la industria farmacéutica. Atención Primaria 2002;29:327-
328 [ Links ]
17. Freemantle N Anderson IM, Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant
illness: a randomized double blind controlled trial. Br J Psychiatry 2000; 177:292-302. [ Links ]
18. Moncrieff J. Are antidepressants overrated? A review of metodological problems in antidepressant trials. J Nerv Ment Dis 2001;
189: 288-295 [ Links ]
19. Mata Ruiz I, Ortiz lobo A. Sesgos y dificultades en la investigación de los nuevos antipsicóticos. Rev Asoc Esp Neuropsiq; 2001,
79: 57-74. [ Links ]
20. Smith R. Maintaining the integrity of the scientific record (editorial). BMJ 2001; 323:588 [ Links ]
21. Sponsorship, authorship, and accountability (editorial). The Lancet 2001; 358: 854-856. [ Links ]
22. Just how tainted has medicine become? (editorial). The Lancet 2002; 359: [ Links ]
23. Fernández Liria A. La nueva desmedicalización de la Psiquiatría. Psiquiatría Pública 1998; 10(2): 81-82. [ Links ]
24. Scandal of scientists who take money for papers ghostwritten by drug companies. The Guardian 7 de Febrero
2002. [ Links ]
25. Gilbody SM, Song F, Eastwood AJ, Sutton A. The causes, consequences and detection of publication bias in psychiatry. Acta
Psychiatr Scand 2000;102: 241.249. [ Links ]
26. Couhdry NK, Stelfox HT, Detsky AS. Relations between Authors of clinical practice guidelines and the pramaceutical industry.
JAMA 2002; 287:612-617 [ Links ]
27. Sheldon TA, Smith GD. Consensus conferences as drug promotion. The Lancet 1993; 334: 100-102. [ Links ]
28. Interacctions with the pharmacuetical Industry: experiences and attitudes of psychiatric residents, interns and clerks. CMAJ,
1995; 153:553 [ Links ]
29. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA 2000; 283: 373-380 [ Links ]
30. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med 1988; 26: 1183-
1189. [ Links ]
31. Lexchin J. Interactions between physicians and pharmaceutical industry. CMAJ 1993; 149: 1401-1407.) [ Links ]
32. Haayer F. Rational prescribing and sources of information. Soc Sci Med 1982; 16: 2017-2023 [ Links ]
33. Wolfe SM. Why do American drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? J
Gen Intern Med 1996; 11: 637-639 [ Links ]
34. Randall T. Kennedy hearings say no more free lunch - or much else - from drug firms. JAMA 1991; 265: 440-442 [ Links ]
35. Coyle SL. Physician-Industry relations. Part 1: individual physicians. Annals of Internal Medicine 2002; 136(5): 396-
402. [ Links ]
36. Komesaroff PA, Kerridge IH. Ethical issues concerning the relations between medical practitiones and the phramaceutical
industry. The medical journal of Australia 2002; 176(3): 118-121 [ Links ]
37. Memoirs of methods used to sell drugs. MaLAM 1999; March/April Vol 17 Nº 3/ 4.
http://www.healthyskepticism.org/editions/IN9903.htm [ Links ]
38. Coyle SL. Physician-Industry relations. Part 2: Organizational issues. Annals of Internal Medicine 2002; 136(5): 403-
406. [ Links ]
39. Bowman MA. The impact of drug company funding on the content of continuing medical education. J Contin Educ Health Prof
1986; 6:66 [ Links ]
40. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical
education. J Contin Educ Health Prof., 1988; 8:13-20) [ Links ]